Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial

Autor: Andrés J M, Ferreri, Kate, Cwynarski, Elisa, Pulczynski, Christopher P, Fox, Elisabeth, Schorb, Claudia, Celico, Monica, Falautano, Alessandro, Nonis, Paul, La Rosée, Mascia, Binder, Alberto, Fabbri, Fiorella, Ilariucci, Mauro, Krampera, Alexander, Roth, Claire, Hemmaway, Peter W, Johnson, Kim M, Linton, Tobias, Pukrop, Jettes Sønderskov, Gørløv, Monica, Balzarotti, Georg, Hess, Ulrich, Keller, Stephan, Stilgenbauer, Jense, Panse, Alessandra, Tucci, Lorella, Orsucci, Francesco, Pisani, Manuela, Zanni, Stefan W, Krause, Hans J, Schmoll, Bernd, Hertenstein, Mathias, Rummel, Jeffery, Smith, Lorenz, Thurner, Giuseppina, Cabras, Elsa, Pennese, Maurilio, Ponzoni, Martina, Deckert, Letterio S, Politi, Jurgen, Finke, Antonella, Ferranti, Kelly, Cozens, Elvira, Burger, Nicoletta, Ielmini, Franco, Cavalli, Emanuele, Zucca, Gerald, Illerhaus

Publikováno v: Ferreri, A J M, Cwynarski, K, Pulczynski, E, Fox, C P, Schorb, E, Celico, C, Falautano, M, Nonis, A, La Rosée, P, Binder, M, Fabbri, A, Ilariucci, F, Krampera, M, Roth, A, Hemmaway, C, Johnson, P W, Linton, K M, Pukrop, T, Gørløv, J S, Balzarotti, M, Hess, G, Keller, U, Stilgenbauer, S, Panse, J, Tucci, A, Orsucci, L, Pisani, F, Zanni, M, Krause, S W, Schmoll, H J, Hertenstein, B, Rummel, M, Smith, J, Thurner, L, Cabras, G, Pennese, E, Ponzoni, M, Deckert, M, Politi, L S, Finke, J, Ferranti, A, Cozens, K, Burger, E, Ielmini, N, Cavalli, F, Zucca, E, Illerhaus, G & IELSG32 study investigators 2022, ' Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma : 7-year results of the IELSG32 randomized trial ', Leukemia, vol. 36, no. 7, pp. 1870-1878 . https://doi.org/10.1038/s41375-022-01582-5

219 HIV-negative adults ≤70 years with primary CNS lymphoma (PCNSL) were enrolled in the randomized IELSG32 trial. Enrolled patients were randomly assigned to receive methotrexate-cytarabine (arm A), or methotrexate-cytarabine-rituximab (B), or met

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca71e062cac7ea0aa1bd288b51b3ad3b
https://pubmed.ncbi.nlm.nih.gov/35562406

Salvage Treatment with Lenalidomide and Dexamethasone In Patients with Relapsed Refractory Mantle Cell Lymphoma: Clinical Results and Modifications of Angiogenic Biomarkers

Autor: C. Rusconi, Flavia Salvi, Fabio Saccona, Francesco Zaja, Caterina Stelitano, Armando Santoro, Ercole Brusamolino, Erika Ravelli, Alessandra Tucci, Renato Fanin, Stefano De Luca, Antonella Ferranti, Ivana Catacchio, Stefano Volpetti, G. Ciccone, Alice Di Rocco, Maurizio Bonfichi, Alessandro Levis, Chiara Bottelli, Roberto Ria, Luca Baldini, Monica Balzarotti, Umberto Vitolo, Stefano Pileri, Lorella Orsucci, Angelo Vacca

Publikováno v: Blood. 116:966-966

Abstract 966 Backgrounds Previous in vivo and in vitro studies have highlighted the activity of Lenalidomide (Len) in patients with relapsed or refractory mantle cell lymphoma (MCL), achieving a 53% overall response rate (ORR), which included 20% com

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::61bd19b6291af01ccc6c0cd19988fccf
https://doi.org/10.1182/blood.v116.21.966.966

Salvage Treatment with Lenalidomide and Dexamethasone in Patients with Relapsed Refractory Mantle Cell Lymphoma

Autor: Renato Fanin, Lorella Orsucci, Luca Baldini, Stefano Volpetti, Umberto Vitolo, Livio Gargantini, Maurizio Bonfichi, Stefano Pileri, Ercole Brusamolino, Alessandra Tucci, Francesco Zaja, Stefano De Luca, Alessandro Levis, Giovannino Ciccone, Chiara Bottelli, Erika Ravelli, Antonella Ferranti, Flavia Salvi, Monica Balzarotti, Armando Santoro, Alice Di Rocco, Caterina Stelitano

Publikováno v: Publons

Abstract 1713 Poster Board I-739 Introduction: Previous reports have highlighted the activity of Lenalidomide (Len) in patients with relapsed or refractory mantle cell lymphoma (MCL), achieving a 53% overall response rate (ORR), which included 20% co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25f2930ad9f4fdea221690f7df072c79
https://doi.org/10.1182/blood.v114.22.1713.1713